EBTATE incorporates Evans Blue (EB) into the somatostatin analog backbone, which significantly enhances uptake by albumin, a virtual slow-release system.
The key feature of the product is that binding the targeting molecule to Evans Blue prolongs the blood half-life and increases its theranostic bioavailability. Long-acting EBTATE has been reported to demonstrate superior in vivo pharmacokinetics and anti-tumor efficacy compared with conventional TATE.